Insider Buying: Phio Pharmaceuticals (NASDAQ:PHIO) CEO Buys $20,500.00 in Stock

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) CEO Robert Bitterman bought 25,000 shares of the company’s stock in a transaction on Monday, November 9th. The stock was bought at an average price of $0.82 per share, for a total transaction of $20,500.00. Following the completion of the purchase, the chief executive officer owned 789,871 shares of the company’s stock, valued at approximately $647,694.22. The trade was a 3.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Phio Pharmaceuticals Price Performance

NASDAQ:PHIO opened at $0.81 on Friday. Phio Pharmaceuticals Corp. has a 1 year low of $0.75 and a 1 year high of $1.88. The business has a fifty day simple moving average of $0.95 and a two-hundred day simple moving average of $1.08.

Phio Pharmaceuticals (NASDAQ:PHIO) last announced its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.36). On average, equities analysts predict that Phio Pharmaceuticals Corp. will post -1.47 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the company. HC Wainwright restated a “buy” rating on shares of Phio Pharmaceuticals in a research report on Wednesday, August 26th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Phio Pharmaceuticals in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $14.00.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a biotechnology company focused on developing cancer immunotherapies. The company’s programs are designed to enhance the immune system’s ability to recognize and destroy tumor cells, with an emphasis on treatments that may be administered directly to the tumor or used in combination with other therapies. Phio’s research is based on its INTASYL self-delivering RNA interference (RNAi) technology. The platform is intended to selectively silence genes involved in immune suppression and cancer progression without requiring a separate delivery vehicle.